New combo injection shows promise for Tough-to-Treat melanoma
NCT ID NCT04796194
First seen Nov 20, 2025 · Last updated May 21, 2026 · Updated 26 times
Summary
This study tested a new drug combination for people with advanced melanoma that no longer responds to standard immunotherapy. The treatment involves injecting LTX-315 directly into tumors along with pembrolizumab, an immunotherapy drug given through the vein. The goal was to see if this approach could shrink tumors or slow the disease. The study included 23 adults with accessible tumors who had exhausted other options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Akershus University Hospital
Lørenskog, Norway
-
Centre Hospitalier Regional Universitaire De Lille
Lille, France
-
Clínica Universidad de Navarra
Pamplona, Spain
-
Gustave Roussy Cancer Campus
Paris, France
-
Hospital Lyon Sud
Pierre-Bénite, France
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Levine Cancer Institute - Atrium Health
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Centre
Houston, Texas, 77030, United States
-
Oslo University Hospital--Radiumhospitalet
Oslo, Norway
-
University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.